Effect of Infliximab in oxidised serum albumin levels during experimental colitis

Biomarkers. 2014 Dec;19(8):693-701. doi: 10.3109/1354750X.2014.982189. Epub 2014 Nov 10.

Abstract

Infliximab (IFX) is widely used in ulcerative colitis and in Crohn's disease treatment. Both diseases are characterised by increased oxidative stress, which may affect albumin oxidation. In order to test this hypothesis, the effect of IFX on colitis induced by dextran sulphate sodium (DSS) in rats was evaluated by measuring the Disease Activity Index, biochemical parameters, serum albumin oxidation and colonic mucosa oxidation. Rats with colitis showed an increase in oxidised serum albumin levels and in the oxidation of colon mucous cells. Both decreased after IFX treatment. This suggests that oxidised albumin could be a useful biomarker for monitoring inflammatory bowel disease.

Keywords: Biomarker; carbonylated albumin; dextran sulfate sodium; inflammatory bowel disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / blood
  • Antibodies, Monoclonal / therapeutic use*
  • Colitis, Ulcerative / metabolism*
  • Enzyme-Linked Immunosorbent Assay
  • Hep G2 Cells
  • Humans
  • Infliximab
  • Male
  • Oxidation-Reduction
  • Rats
  • Rats, Wistar
  • Serum Albumin / metabolism*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Antibodies, Monoclonal
  • Serum Albumin
  • Tumor Necrosis Factor-alpha
  • Infliximab